These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 8710158)

  • 41. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
    Tarng DC; Huang TP; Chen TW; Yang WC
    Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determinants of circulating soluble transferrin receptor level in chronic haemodialysis patients.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 2002 Jun; 17(6):1063-9. PubMed ID: 12032198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
    Tarng DC; Huang TP; Chen TW
    Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients.
    Greenbaum LA; Pan CG; Caley C; Nelson T; Sheth KJ
    Pediatr Nephrol; 2000 Sep; 14(10-11):908-11. PubMed ID: 10975297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of intravenous iron therapy on novel markers of iron deficiency.
    Chinnappa S; Bhandari S
    Int J Artif Organs; 2010 May; 33(5):297-301. PubMed ID: 20593351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reticulocyte indices in patients with end stage renal disease on hemodialysis.
    Bhandari S; Turney JH; Brownjohn AM; Norfolk D
    J Nephrol; 1998; 11(2):78-82. PubMed ID: 9589378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Washing erythrocytes to remove interferents in measurements of zinc protoporphyrin by front-face hematofluorometry.
    Hastka J; Lasserre JJ; Schwarzbeck A; Strauch M; Hehlmann R
    Clin Chem; 1992 Nov; 38(11):2184-9. PubMed ID: 1424108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erythrocyte zinc protoporphyrin.
    Braun J
    Kidney Int Suppl; 1999 Mar; 69():S57-60. PubMed ID: 10084287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients.
    Albitar S; Meulders Q; Hammoud H; Soutif C; Bouvier P; Pollini J
    Nephrol Dial Transplant; 1995; 10 Suppl 6():40-3. PubMed ID: 8524493
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy.
    Caravaca F; Vagace JM; Aparicio A; Groiss J; Pizarro JL; Alonso N; Garcia MC; Arrobas M; Cubero J; Esparrago J
    Am J Kidney Dis; 1992 Sep; 20(3):249-54. PubMed ID: 1519605
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin.
    Baart AM; van Noord PA; Vergouwe Y; Moons KG; Swinkels DW; Wiegerinck ET; de Kort WL; Atsma F
    Transfusion; 2013 Aug; 53(8):1670-7. PubMed ID: 23176175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients.
    Takasawa K; Takaeda C; Maeda T; Ueda N
    Nutrients; 2014 Dec; 7(1):103-18. PubMed ID: 25551249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Soluble transferrin receptor and zinc protoporphyrin--competitors or efficient partners?
    Metzgeroth G; Adelberger V; Dorn-Beineke A; Kuhn C; Schatz M; Maywald O; Bertsch T; Wisser H; Hehlmann R; Hastka J
    Eur J Haematol; 2005 Oct; 75(4):309-17. PubMed ID: 16146537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum transferrin receptor in children: usefulness for determinating the nature of anemia in infection.
    Angeles Vázquez López M; Molinos FL; Carmona ML; Morales AC; Muñoz Vico FJ; Muñoz JL; Muñoz Hoyos A
    J Pediatr Hematol Oncol; 2006 Dec; 28(12):809-15. PubMed ID: 17164650
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of reticulocyte hemoglobin equivalent with traditional markers of iron and erythropoiesis in pediatric dialysis.
    Davidkova S; Prestidge TD; Reed PW; Kara T; Wong W; Prestidge C
    Pediatr Nephrol; 2016 May; 31(5):819-26. PubMed ID: 26667237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
    Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
    Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing iron status: beyond serum ferritin and transferrin saturation.
    Wish JB
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S4-8. PubMed ID: 17699374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of iron status in patients on chronic hemodialysis: relative usefulness of bone marrow hemosiderin, serum ferritin, transferrin saturation, mean corpuscular volume and red cell protoporphyrin.
    Moreb J; Popovtzer MM; Friedlaender MM; Konijn AM; Hershko C
    Nephron; 1983; 35(3):196-200. PubMed ID: 6633760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.